Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review
BJU International · 2024-10 · 134 (4) · 541-550
DOI: 10.1111/bju.16368 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BJU International, online erschienen am 24.04.2024. Verfasst von Philipp Maisch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Immunotherapy, Urologic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
To assess the effects of immunotherapy compared to chemotherapy as first‐ and second‐line treatment of advanced or metastatic urothelial carcinoma.
Methods
Based on a published protocol, we performed a systematic search of multiple databases. Two review authors independently performed the literature selection, identified relevant studies, assessed the eligibility of studies for inclusion, and extracted data. We performed statistical analyses using a random‐effects model and assessed the quality of the evidence on a per‐outcome basis according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
Results
We included five randomised controlled trials and also identified seven single‐arm studies. When used as first‐line therapy, immunotherapy probably has little to no effect on the risk of death from any cause compared to chemotherapy (hazard ratio [HR] 0.97, 95% confidence interval [CI] 0.87–1.07; moderate‐certainty evidence). immunotherapy probably has little to no effect on health‐related quality of life (mean difference [MD] 4.10, 95% CI 3.83–4.37; moderate). Immunotherapy probably reduces grade 3–5 adverse events (risk ratio [RR] 0.47, 95% CI 0.29–0.75; moderate). In the second‐line setting immunotherapy may reduce the risk of death from any cause (HR 0.72, 95% CI 0.63–0.81; low). Immunotherapy may have little to no effect on health‐related quality of life when compared to chemotherapy (MD 4.82, 95% CI −3.11 to 12.75; low). Immunotherapy may reduce grade 3–5 adverse events (RR 0.89, 95% CI 0.81–0.97; low).
Conclusions
Compared to chemotherapy, immunotherapy has little to no effect on the risk of death from any cause in a first‐line setting. Nevertheless, it may reduce the risk of death from any cause when used as second‐line therapy. The health‐related quality of life of participants receiving first‐ and second‐line therapy does not appear to be affected by immunotherapy. Immunotherapy probably reduces or may reduce grade 3–5 adverse events when used as first‐ and second‐line therapy, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany.
- Department of Urology and Pediatric Urology, University Hospital Ulm, University of Ulm, Ulm, Germany.
- Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
- Graduate School, Yonsei University Wonju College of Medicine, Wonju, South Korea.
- Department of Urology, Emory University, Atlanta, GA, USA.
- Dr. John Archer Library, University of Regina, Regina, SK, Canada.
ORCID-Profile: Philipp Maisch, Eu Chang Hwang, Philipp Dahm
Zitieren
APA
Maisch, P., Hwang, E. C., Kim, K., Narayan, V. M., Bakker, C., Kunath, F., & Dahm, P. (2024). Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review. BJU International, 134(4), 541-550. https://doi.org/10.1111/bju.16368
Vancouver
Maisch P, Hwang EC, Kim K, Narayan VM, Bakker C, Kunath F, et al. Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review. BJU International. 2024;134(4):541-550. doi:10.1111/bju.16368
BibTeX
@article{Maisch2024,
author = {Maisch, Philipp and Hwang, Eu Chang and Kim, Kwangmin and Narayan, Vikram M and Bakker, Caitlin and Kunath, Frank and Dahm, Philipp},
title = {Immunotherapy for advanced or metastatic urothelial carcinoma: an abridged Cochrane review},
journal = {BJU International},
year = {2024},
volume = {134},
number = {4},
pages = {541--550},
doi = {10.1111/bju.16368}
}
EUVIMED